UNLIMITED TURBO BULL - BIOGEN IDEC | Real-time Euronext Paris 01:03:10 15/05/2024 pm IST | ||
| 1.22 EUR | +5.63% |
|
| Current month | +9.48% | ||
| 1 month | +56.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 1.22 | +5.63% |
| 14/24/14 | 1.155 | -0.86% |
| 13/24/13 | 1.165 | +2.64% |
| 10/24/10 | 1.135 | +2.71% |
| 09/24/09 | 1.105 | +0.91% |
Real-time Euronext Paris
Last update May 15, 2024 at 01:03 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Société Générale
|
| 518CS | |
| ISIN | DE000SU1EGN3 |
| Date issued | 31/10/2023 |
| Strike | 162 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 1.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.07 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.04 € |
| Spread % | 3.25% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
226.9
USD
Average target price
285.9
USD
Spread / Average Target
+26.02%
- Stock Market
- Certificates
- 518CS Certificat